WHAT S THE SKINNY ON WEIGHT LOSS MEDICATION SAFETY? January 25, 2019 Pennsylvania Pharmacists Association
|
|
- Christina Dean
- 5 years ago
- Views:
Transcription
1 WHAT S THE SKINNY ON WEIGHT LOSS MEDICATION SAFETY? January 25, 2019 Pennsylvania Pharmacists Association
2 MEGAN N DUNLOP, PHARMD, CTTS CLINICAL PHARMACIST, UPMC COMMUNITY PROVIDER SERVICES
3 LEARNING OBJECTIVES Identify some commonly used weight loss medications and supplements Recall side effects associated with weight loss medications Recommend safe weight-loss strategies to patients using patient cases Apply safe weight-loss strategies to your own patient populations through group discussion
4 BACKGROUND Almost 70% of the US adult population is overweight (BMI ) or obese (BMI 30+) 32% of US children are overweight or obese A diet high in carbohydrates and fats will Impair the hormone leptin (appetite suppressor) Increase the hormone ghrelin (which increases appetite) Most effective diets based on calorie deficit (3500 kcal= 1 pound) 2013 Guidelines for Management of Overweight and Obesity
5 COMMON MEDICATIONS THAT CAUSE WEIGHT GAIN Insulins Prednisone and other corticosteroids Pregabalin, gabapentin Tricyclic antidepressants SSRIs Antipsychotics Lithium Dronabinol 2013 Guidelines for Management of Overweight and Obesity
6 WEIGHT LOSS MEDICATIONS
7 Indication: Short term (a few weeks) adjunct for weight loss along with diet and exercise for adults with BMI > 30 kg/m 2 BMI > 27 kg/m 2 with presence of risk factors (diabetes, hypertension) Dose: 37.5 mg daily for most patients, but use smallest amount needed for patient Class: Structurally related to amphetamines, anorexitic Teva. Adipex-P Package insert.
8 ADIPEX-P Contraindications History of CVD Hypothyroidism Glaucoma Agitated states History of drug abuse Pregnancy/ nursing Warnings and Precautions Primary Pulmonary Hypertension Valvular Heart Disease Tolerance (must discontinue, not increase dose) Risk of abuse and dependence Risk of reactions when used with alcohol (increased CVD risk, increased effect alcohol) Caution in HTN Caution in Diabetes with use of insulin/ hypoglycemic agents Teva. Adipex-P Package insert.
9 SO IS IT WORTH IT? The magnitude of increased weight-loss in drug-treated patients over placebo-treated patients is only a fraction of a pound per week Anorexitic effect lasts only weeks Too many patient-specific factors to standardize studies Not a substitute to diet and exercise Teva. Adipex-P Package insert
10 Mechanism: naltrexone decreases food cravings while bupropion decreases appetite Dose: Week 1: 1 tablet every morning Week 2: 1 tablet BID Week 3: 2 tablets every morning and 1 every evening Week 4 and beyond: 2 tablets BID Patient Counseling: Swallow whole, do not take with high fat meal Side effects: NV, constipation, headache, dizziness, dry mouth, sleep disorder, increased BP and HR risk highest in 1 st 3 months Pharm Management of Obesity. J Clin Endocrinol Metab.
11 CONTRAVE Contraindications Chronic opioid use naltrexone will block opioids and their analgesic effect. Must discontinue 7-10 days before starting Contrave Seizure disorder Abrupt discontinuation of alcohol Uncontrolled hypertention Use of other bupropion-containing products Eating disorders Use of MAO inhibitors, linezolid or methylene blue Pregnancy Warnings and Precautions Boxed Warning: Suicidal ideation in children and young adults (due to the bupropion component) Seizure risk Hepatotoxicity Pregnancy Category X Pharm Management of Obesity. J Clin Endocrinol Metab.
12 SO IS IT WORTH IT? ~ 11 pounds average weight loss If patient has not lost 5% or more of body weight in 12 weeks, discontinue medication Pharm Management of Obesity. J Clin Endocrinol Metab.
13 REMS Program: Monthly pregnancy test due to teratogenicity Mechanism: blocking glutamate receptors and weak inhibition of carbonic anhydraseleads to decreased appetite Dose: Start with 3.75/23 mg tablet po qam for 14 days, then titrate up based on weight loss Max dose 15/92 mg daily If Crcl < 50 ml/min, max dose is 7.5/46 mg daily Side effects: Dizziness, tachycardia, headache, cognitive impairment, constipation, dry mouth, insomnia Vivus, Inc. Qsymia.
14 QSYMIA Contraindications Hypothyroidism Glaucoma MAO inhibitor use in last 14 days Pregnancy/ lactation Warnings and Precautions Pregnancy Category X Do not abruptly discontinue seizure risk Pharm Management of Obesity. J Clin Endocrinol Metab.
15 SO IS IT WORTH IT? ~19 pound average weight loss If patient has not lost 5% or more of body weight in 12 weeks, discontinue medication Pharm Management of Obesity. J Clin Endocrinol Metab.
16 Mechanism: Serotonin 5-HT receptor agonist, increases satiety resulting in weight loss Dose: 10 mg po BID Side effects: Headache, dizziness, fatigue, nausea, dry mouth, constipation, hypoglycemia Note: FDA requires manufacture to monitor cardiovascular outcomes Easai, Inc. Belviq.
17 BELVIQ Contraindications Pregnancy Category X Warnings and Precautions Valvular heart disease Serotonin syndrome CNS effects Decreased WBC, RBC Psychiatric disorders Priapism Pharm Management of Obesity. J Clin Endocrinol Metab.
18 SO IS IT WORTH IT? ~8 pound average weight loss If patient has not lost 5% or more of body weight in 12 weeks, discontinue medication Pharm Management of Obesity. J Clin Endocrinol Metab.
19 Mechanism: Long-term lipase inhibitor that decreases the absorption of dietary fat by ~30% Dose: Rx 120 mg po with each meal containing fat OTC 60 mg with each meal containing fat Rx Orlistat only weight loss medication approved in children (ages 12+) Must take multivitamin to replace fat soluble vitamins lost (A,D,E,K) separate medications Side effects: GI upset, flatulence with discharge, fecal urgency, fatty stool H2 Pharma. Xenical.
20 ORLISTAT Contraindications Pregnancy Malabsorption syndromes Cholestasis Warnings and Precautions Liver damage Kidney stones Hypoglycemia Pharm Management of Obesity. J Clin Endocrinol Metab.
21 SO IS IT WORTH IT? Efficacy depends on diet Most cannot tolerate GI effects If patient has not lost 5% or more of body weight in 12 weeks, discontinue medication Pharm Management of Obesity. J Clin Endocrinol Metab.
22 WHICH OF THE FOLLOWING IS A SERIOUS ADVERSE DRUG REACTION ASSOCIATED WITH ADIPEX-P (PHENTERMINE HCL)? A. Red Man Syndrome B. Valvular Heart Disease C. Liver Failure D. Muscular atrophy
23 WHICH HORMONE NATURALLY SUPPRESSES APPETITE? A. Leptin B. Ghrelin C. Aldosterone D. Testosterone
24 WHICH WEIGHT LOSS MEDICATION MENTIONED IS THE ONLY WITH A REMS PROGRAM? A. Adipex B. Contrave C. Qsymia D. Alli
25 WHAT METHODS CAN WE TEACH?
26 ADA WEIGHT LOSS METHODS Mediterranean Diet DASH Diet Low carb/ low fat diets Plate Method Nutrition labels and calorie counting
27 PLATE METHOD Create Your Plate. American Diabetes Association.
28 NUTRITION LABELS US Food and Drug. Nutrition Facts.
29 PATIENT CASE AP is a 31 yo female who is 195 lbs and 5 4 tall. She has major depressive disorder, for which she takes Wellbutrin XL 150 mg po qd. She also takes a multivitamin. She has no other medications and otherwise lives a healthy lifestyle. AP lives with her husband and two dogs, and is interested in becoming pregnant within the next year. AP has tried diet and exercise, and has even consulted a nutritionist, but is not having any luck loosing weight. She asks you if there is any kind of pill she could take that would help? Which, if any, weight loss medication would you suggest? What would you tell her about it?
30 PATIENT CASE PK is a 68 yo male with Type II Diabetes (controlled with metformin and glipizide) that comes to your pharmacy for Diabetes Self Management Education. PK is 5 11 and weighs 237 lbs. He was recently told by his doctor that if he doesn t loose weight, he may have to go on insulin some day, and he really does not want that to happen. In addition to diabetes, PK also has high blood pressure, for which he takes lisinopril, and hypercholesterolemia, for which he takes atorvastatin. You learned at DSME class that he is a widower and often eats fast food or a TV dinner for every meal. Which, if any, weight loss medication would you suggest for him? What other weight loss advice might you give him?
31 DISCUSSION How can you incorporate this information into your own practices?
32 THANK YOU! Questions?
33 RESOURCES 2013 AHA/ACC/TOS Guideline for the management of Overweight and Obesity in Adults: A Report of thr American College of Cardiology/AHA Task Force on Practice Guidelines and the Obesity Society. J Am Coll Cardiol. 2014; 63: Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100(2): Teva. Adipex Teva Pharmaceuticals USA. Adipex-P Package Insert Nalpropion Pharmaceuticals, Inc. Contrave D_BwE. Vivus, Inc. Qsymia Easai, Inc. Belviq H2 Pharma, LLC. Xenical American Diabetes Association. Create Your Plate US Food and Drug Administration. How to Understand and Use the Nutrition Facts Label
An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD
An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD Sanford I. Weill Professor of Metabolic Research Director of the Comprehensive Weight Control Program Weill Cornell Medical College
More informationObesity Pharmacotherapy: Options and Applications in Clinical Practice. Scott Kahan, MD, MPH
Obesity Pharmacotherapy: Options and Applications in Clinical Practice Scott Kahan, MD, MPH Obesity Pharmacotherapy Few providers prescribe pharmacotherapy. Few patients use pharmacotherapy. Pharmacotherapy
More informationRealistic Expectations: Drugs in the Treatment of Obesity. Lora Cotton, D.O. January 20, 2013
Realistic Expectations: Drugs in the Treatment of Obesity Lora Cotton, D.O. January 20, 2013 Overview Approach FDA approved agents will be covered FDA approval guidelines Candidates Expectations Mechanisms,
More informationWEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM?
WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM? THE OBESITY MEDICINE ASSOCIATION S DEFINITION OF OBESITY Obesity is defined as a chronic, relapsing, multi-factorial, neurobehavioral disease, wherein
More informationUnderstanding Obesity: The Causes, Effects, and Treatment Options
Understanding Obesity: The Causes, Effects, and Treatment Options Jeffrey Sicat, MD, FACE Virginia Association of Clinical Nurse Specialists September 29, 2017 Objectives By the end of this discussion,
More informationWithout Background for printing as Pocket Reference
Without Background for printing as Pocket Reference Diabetes Prevention Program 1 LOOK AHEAD 3 Multi-center trial in patients with impaired glucose tolerance Weight loss of 7% reduced the rate of progression
More informationReduce hunger and help control cravings with CONTRAVE
Reduce hunger and help control cravings with CONTRAVE Understanding and identifying patients who are ready to start their weight-loss journey with CONTRAVE is key to helping them reach their weight-loss
More informationWhen Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity
When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity Casey Bonaquist, DO Saturday, April 30 th, 2016 17 th Annual Primary Care & Cardiovascular Symposium Learning Objectives After
More informationLearning Objectives. Currently Available Options. Update on Weight Loss Pharmacotherapy. Dan Bessesen, MD
Update on Weight Loss Pharmacotherapy Dan Bessesen, MD Daniel.bessesen@ucdenver.edu Learning Objectives List the medications that are currently available for the treatment of obesity, describe their mechanisms
More informationObesity Management in Type 2 Diabetes
Obesity Management in Type 2 Diabetes Clare J. Lee, MD, MHS Assistant Professor of Medicine, Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins University Disclosures None Objectives Describe
More informationAnti-Obesity Agents Drug Class Prior Authorization Protocol
Anti-Obesity Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: March 1, 2018 This policy has been developed through review
More informationWhat Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels?
What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? Daniel Bessesen, MD Professor of Medicine University of Colorado School of Medicine Chief of Endocrinology,
More informationPutting It in Perspective Using Medications for Chronic Weight Management. Donna H. Ryan, MD Pennington Biomedical Research Center
Putting It in Perspective Using Medications for Chronic Weight Management Donna H. Ryan, MD Pennington Biomedical Research Center ryandh@pbrc.edu Why Use Medications? Medications help patients lose more
More informationObesity: Pharmacologic and Surgical Management
Obesity: Pharmacologic and Surgical Management ADRIENNE YOUDIM, MD, FACP ASSOCIATE PROFESSOR OF MEDICINE, UCLA ASSISTANT PROFESSOR OF MEDICINE, CEDARS SINAI MEDICAL CENTER JANUARY 2018 Defining Obesity
More informationMedical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy. Shelby Sullivan University of Colorado School Of Medicine
Medical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy Shelby Sullivan University of Colorado School Of Medicine Disclosures Research Support / Grants R01DK094483-02 Klein/Mittendorfer
More informationMEDICAL MANAGEMENT 101
MEDICAL MANAGEMENT 101 Christopher Still, DO, FACN, FACP Medical Director, Center for Nutrition & Weight Management Director, Geisinger Obesity Research Institute Geisinger Health Care System Your Weight
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
1:55-2:4pm Medical Management of Obesity: Lifestyle, Medicine, and Surgery SPEAKER Osama Hamdy, MD, PhD, FACE Disclosures The following relationships exist related to this presentation: Osama Hamdy, MD,
More informationManagement of Obesity. Objectives. Background Impact and scope of Obesity. Control of Energy Homeostasis Methods of treatment Medications.
Medical Management of Obesity Ben O Donnell, MD 1 Objectives Background Impact and scope of Obesity Control of Energy Homeostasis Methods of treatment Medications 2 O'Donnell 1 Impact of Obesity According
More informationCONTRAVE Summary Brand Usage Guidelines for Third Parties
CONTRAVE We thank you for your interest in using the CONTRAVE brand assets to help educate patients struggling to lose weight. This summary document is for reference only. In accordance with the CONTRAVE
More informationOverview of Management of Obesity
Overview of Management of Obesity Srividya Kidambi, MD, MS Division of Endocrinology, Metabolism, and Clinical Nutrition Medical College of Wisconsin, Milwaukee, WI I have nothing to disclose. Objectives
More informationThe New Trend of Anti-Obesity Drug
2016 년대한당뇨병학회춘계학술대회 The New Trend of Anti-Obesity Drug MIN-SEON KIM ASAN MEDICAL CENTER Conflict of Interest Nothing to declare Index Introduction: Obesity Epidemiology, Pathophysiology and Comorbidity
More informationHealthy weight 18.5 to <25. Diabetes Dispatch. Overweight 25 to <30. Obese class I 30 to <35. Obese class II 35 to <40
A L A S K A N A T I V E D I A B E T E S T E A M Diabetes Dispatch Volume 10, Issue 4 Winter 2015 T he American Medical Association, the World Health Organization, and the US Food and Drug Administration
More informationApproaches to Prevention and Management of Obesity Maj Sarah Kelly USAF
CPE Information and Disclosures Approaches to Prevention and Management of Obesity Maj Sarah Kelly USAF Sarah Kelly declares that she owns stock in the following companies: Pfizer Medtronic The American
More informationTreating Obesity- NOT Just with Surgery
Treating Obesity- NOT Just with Surgery Identify obesity as a major health problem Define and describe causes of obesity with contributing factors. Discuss pertinent details to seeing an obese patient
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationWhere are We Now? Editor s Note: Who Qualifi es for Obesity Medications?
Obesity Medications Where are We Now? by Christopher D. Still, DO, FACP, FACN, Nadia Boulghassoul-Pietrzykowska, MD, and Jennifer E. Franceschelli, DO Editor s Note: Please note that some of the medications
More informationattempts to commit suicide acting aggressive, being angry, or violent
Medication Guide CONTRAVE (CON-trayv) (naltrexone HCl and bupropion HCl) Extended-Release Tablets Read this Medication Guide before you start taking CONTRAVE and each time you get a refill. There may be
More informationPHENTERMINE INFORMATION SHEET
PHENTERMINE INFORMATION SHEET What is phentermine? Phentermine is a prescription weight loss medication. It is an appetite suppressant. Individuals taking phentermine lose weight because they are less
More informationFDA approves Belviq to treat some overweight or obese adults
FDA approves Belviq to treat some overweight or obese adults Silver Spring, MD, USA (June 27, 2012) - The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition
More informationI. ALL CLAIMS: HEALTH CARE PROFESSIONALS
HCP Prescribing Information Date/Version January 2015 Version 2 Page: 1 of 5 I. ALL CLAIMS: HEALTH CARE PROFESSIONALS Indications and Usage Saxenda (liraglutide [rdna origin] injection) is indicated as
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1172-3 Program Prior Authorization - California and New York Regulatory Program - Weight Loss Medication Includes both brand and
More informationOverview Purpose Complete the Qsymia Pharmacy Certification in 3 easy steps:
Overview The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia to ensure the benefits of Qsymia outweigh the increased risk of teratogenicity.
More informationOverview. Purpose. Qsymia (phentermine and topiramate extended-release) capsules CIV Pharmacy Training Program
Qsymia (phentermine and topiramate extended-release) capsules CIV Pharmacy Training Program Overview The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS)
More information2. Is the request for Alli, Xenical or Belviq? Y N. 3. Has the patient received 6 months or more of therapy? Y N
Prior Authorization MERC CARE PLA Weight Reduction Medications (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.
More informationClinical Policy: Weight Loss Reference Number: CP.CPA.197 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.197 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationFaculty Disclosures. Vera Tarman, MD, Author:
Faculty Disclosures Vera Tarman, MD, Author: Food Junkies: The Truth About Food Addiction (book) Dangerous Liaisons: Comfort and Food (DVD) Biology of Addiction, Biology of Recovery (DVDs) Standard Treatments
More informationComplete the Qsymia Healthcare Provider Training Program in 2 easy steps:
Overview FDA has required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia so that healthcare providers can be informed about the increased risk of teratogenicity associated with Qsymia therapy.
More informationNavigating the new weight loss medications Jacqueline Jordan Spiegel, MS, PA-C, DFAAPA Associate Professor Midwestern University
Navigating the new weight loss medications Jacqueline Jordan Spiegel, MS, PA-C, DFAAPA Associate Professor Midwestern University Objectives Discuss the evolution of obesity as a diagnosis and disease.
More informationClinical Policy: Weight Loss Reference Number: CP.CPA.200 Effective Date: Last Review Date: Line of Business: Commercial - HNCA
Clinical Policy: Reference Number: CP.CPA.200 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial - HNCA Revision Log See Important Reminder at the end of this policy for important
More informationOverweight and Obesity on the Menu. Marwan Akel, Pharm. D, MPH Clinical Assistant Professor School of Pharmacy Lebanese International University
Overweight and Obesity on the Menu Marwan Akel, Pharm. D, MPH Clinical Assistant Professor School of Pharmacy Lebanese International University Prevention The most efficient and cost-effective approach
More informationHow to Achieve Medical Weight Loss in 2012
How to Achieve Medical Weight Loss in 2012 Gary D. Foster, Ph.D. Laure H. Carnell Professor of Medicine, Public Health, and Psychology Director, Center for Obesity Research and Education Temple University
More informationIdentification, Evaluation, and Treatment of Overweight and Obesity in Adults Clinical Practice Guideline MedStar Health
Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making
More informationCravings are one of the main reasons diets fail
? Did you KNOW Cravings are one of the main reasons diets fail Help control your cravings and lose weight with CONTRAVE Actual patient. Results not typical. Across three studies, 46% of patients taking
More informationUpdate on the Recent Advances in Obesity Management. Benjamin O Donnell, MD Oct 5 th, 2018
Update on the Recent Advances in Obesity Management Benjamin O Donnell, MD Oct 5 th, 2018 Objectives Background Control of Energy Homeostasis Approach to Diet and Exercise Medications Recently Approved
More informationUpdate on Treating Obesity: A Multidisciplinary Approach. Marie Harkins, FNP BC, CDE Cayuga Center for Healthy Living
Update on Treating Obesity: A Multidisciplinary Approach Marie Harkins, FNP BC, CDE Cayuga Center for Healthy Living Objectives 1. Define obesity as a disease 2. List the stepwise approach to obesity treatment
More informationDEKALB WOMEN S SPECIALISTS 5295 HWY 78 STE. N STONE MOUNTAIN, GA
DEKALB WOMEN S SPECIALISTS 5295 HWY 78 STE. N STONE MOUNTAIN, GA.30087 404-508-2000 WWW.DEKALBWOMEN.COM * PATIENT INFORMATION FORM FOR WEIGHT LOSS * TODAY S DATE: PATIENTS NAME: STREET ADDRESS: CITY /
More information9 out of 10 people struggle with food cravings while dieting?
CONTRAVE IS THE #1 PRESCRIBED WEIGHT-LOSS BRAND* DID YOU KNOW... 9 out of 10 people struggle with food cravings while dieting? Help control your cravings and lose weight with CONTRAVE The exact neurochemical
More information9 out of 10 people struggle with food cravings while dieting?
CONTRAVE IS THE #1 PRESCRIBED WEIGHT-LOSS BRAND* DID YOU KNOW... 9 out of 10 people struggle with food cravings while dieting? Help control your cravings and lose weight with CONTRAVE The exact neurochemical
More informationIdentification, Evaluation, and Treatment of Overweight and Obesity in Adults
Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making
More informationSystem): Rapid-Acting Inhaled Insulin for the Treatment of Diabetes
Volume 30, Issue 2 November 2014 Afrezza (Technosphere Insulin Inhalation System): Rapid-Acting Inhaled Insulin for the Treatment of Diabetes Merly Suarez, PharmD Candidate D P PharmacodynamicsandPharmacokinetics
More informationThe prevalence of obesity in adults has doubled over the past 30 years
Obesity in America: Facts and Fiction MICHAEL G. PERRI, PhD Professor, Clinical and Health Psychology Interim Dean, College of Public Health and Health Professions University of Florida Overview: Key Questions
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationPhentermine Hydrochloride
Weight Loss Medications Phentermine Hydrochloride Drug Enforcement Agency DEA: Schedule IV drug Indications: It is approved as monotherapy as a weight loss drug Doses To be taken once a day in the morning
More informationManaging Obesity as a Disease. Disclosure. Objectives
Managing Obesity as a Disease Ji Hyun Chun (CJ), PA-C, BC-ADM OptumCare Medical Group: Endocrinology, Irvine, CA President, American Society of Endocrine PAs none Disclosure Objectives Recognize obesity
More informationDonna H Ryan, MD, FACP Pennington Biomedical Research Center Baton Rouge, LA.
Donna H Ryan, MD, FACP Pennington Biomedical Research Center Baton Rouge, LA Donna.Ryan@pbrc.edu National Summit on Health Disparities April 22, 2013 Disclosure Dr. Ryan has served as an advisor to Nutrisystem
More informationFaculty/Presenter Disclosure
Weight loss & Obesity WHAT S NEW & EXCITING? Tina Korownyk Dept of Family Medicine, UofA Faculty/Presenter Disclosure Faculty/Presenter: Tina Korownyk Relationships with commercial interests: None 1 Drowning
More informationObesity: The Role of Pharmacotherapy The Annual Women s & Children s Health Update Saturday 17th February 2018 Benefits of modest weight loss 3-10%
Obesity: The Role of Pharmacotherapy Professor John B Dixon, MBBS PhD Professorial Research Fellow Head, Clinical Obesity Research Baker IDI Heart & Diabetes Institute Melbourne, Australia The Annual Women
More informationThe US FDA, EMA and our TGA use these cutpoints in assessing drug efficacy. Disclosures: Professor John B Dixon
Obesity: The Role of Pharmacotherapy Professor John B Dixon, MBBS PhD Professorial Research Fellow Head, Clinical Obesity Research Baker IDI Heart & Diabetes Institute Melbourne, Australia The Annual Women
More informationTreat-to-Target Tools
TEAMcare Care Manager Primary Care Provider Treat to Target Discussion Tool for Treatment Enhancement Activation and Motivation (TEAM) Depression, Diabetes and Coronary Heart Disease (CHD) Intervention
More informationReview of Pharmacologic Weight Loss Medications in a Patient-Centered Medical Home
604858PMTXXX10.1177/8755122515604858Journal of Pharmacy TechnologyCostello et al research-article2015 Case report Review of Pharmacologic Weight Loss Medications in a Patient-Centered Medical Home Journal
More informationPast, Present and Future of Pharmacotherapy for Obesity
Past, Present and Future of Pharmacotherapy for Obesity Dan Bessesen, MD Chief of Endocrinology; Denver Health Medical Center Professor of Medicine, University of Colorado School of Medicine Daniel.Bessesen@ucdenver.edu
More informationTEAMcare Treat-to-Target Tools
TEAMcare Treat-to-Target Tools The TEAMcare Treatment Discussion Tool (treatment protocol) Nurse Case Manager (NCM)-MD Treat-to-Target Discussion Tool for Treatment Enhancement Activation and Motivation
More informationCopyright 2017 by Sea Courses Inc.
Appetite Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical,
More informationBrand Name: Belviq. Generic Name: lorcaserin hydrochloride. Manufacturer 3 : Eisai Inc. Drug Class 1,2 : Serotonin 5-HT 2C Receptor Agonist
Brand Name: Belviq Generic Name: lorcaserin hydrochloride Manufacturer 3 : Eisai Inc. Drug Class 1,2 : Serotonin 5-HT 2C Receptor Agonist Uses: Labeled Uses 1,2,3,4,5 : Adjunctive treatment for obesity
More informationTreatment of Obesity SAJIDA AHAD MERCY GENERAL SURGERY
Treatment of Obesity SAJIDA AHAD MERCY GENERAL SURGERY Objectives 1. Learn classification and evaluation of overweight and obese patient 2. Discuss impact of voluntary weight loss on morbidity and mortality
More informationWhat s the Skinny?: An Update on Medications for Weight Management
What s the Skinny?: An Update on Medications for Weight Management Katura C. Bullock, PharmD, BCPS Associate Professor UNT System College of Pharmacy SESSION OBJECTIVES 1. Recognize the prevalence of obesity
More informationOverview of the Pharmacologic & Surgical Treatment for Obesity
Overview of the Pharmacologic & Surgical Treatment for Obesity Christopher D. Still, DO, FACN, FACP. FTOS Medical Director, Center for Nutrition & Weight Management Director, Geisinger Obesity Research
More informationObesity Epidemic (Approaches to its Treatment) Ricardo Correa, M.D., Es.D., F.A.C.P., F.A.C.R., C.M.Q.
Obesity Epidemic (Approaches to its Treatment) Ricardo Correa, M.D., Es.D., F.A.C.P., F.A.C.R., C.M.Q. Assistant Professor of Medicine University of Arizona College of Medicine-Phoenix and The Warren Alpert
More informationWhat else do I need to know about antidepressant medicines?
MEDICATION GUIDE Bupropion (bue-proe-pee-on) Hydrochloride Extended-Release Tablets (SR), 200 mg Read this Medication Guide carefully before you start taking bupropion hydrochloride extended-release tablets
More information1 Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. Endocr Pract. 2012;18: Depression. Cancer. Gallbladder Disease
Percent 4 3 2 1 Obese Overweight Extremely obese Note: Age-adjusted by the direct method to the year 2 US Bureau of the Census using age groups 2 39, 4 59, and 6 74 years. Pregnant females excluded. Overweight
More informationSurgical History Please list all operations and dates:
1 General Information *Please complete in blue or black ink only* Name: Date: Address: City: State: Zip Code: Date of Birth: Email: Telephone: (Cell) (Home) (Work) Referred by: Occupation: Primary Doctor:
More informationTreatment of Obesity: Diets, Drugs and Surgery
Treatment of Obesity: Diets, Drugs and Surgery Disclosures None Michelle Guy, MD Professor Clinical Medicine University of California San Francisco Diplomate American Board of Obesity Medicine Objectives
More informationNorpramin (desipramine)
Generic name: Desipramine Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets Available in generic: Yes Drug class: Tricyclic antidepressant General Information Norpramin (desipramine)
More informationTO PHARMACIST: PLEASE PROVIDE THIS INFORMATION TO THE PATIENT. Important Patient Information. Patient Information about XENICAL (orlistat) Capsules
TO PHARMACIST: PLEASE PROVIDE THIS INFORMATION TO THE PATIENT. Important Patient Information Patient Information about XENICAL (orlistat) Capsules XENICAL (zen i-cal) Generic Name: orlistat Please read
More informationPHENTERMINE INFORMED CONSENT
PHENTERMINE INFORMED CONSENT I request the use of Phentermine, along with strict dietary restrictions for the purpose of weight loss. I understand that as part of the program, I will be given a limited
More informationThe ABCDs of Obesity
The ABCDs of Obesity Adipose Based Chronic Disease Michael A. Bush, M.D. Clinical Chief, Division of Endocrinology Cedars-Sinai Medical Center Clinical Associate Professor, Geffen School of Medicine, UCLA
More informationWellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion)
Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion) Generic name: Bupropion Available strengths: 75 mg, 100 mg immediate-release tablets; 100 mg, 150 mg, 200 mg sustained-release tablets (Wellbutrin-SR);
More informationObesity and Bariatric Surgery
Obesity and Bariatric Surgery Disclosure Nothing to disclose Subhashini Ayloo MD, MPH, FACS Associate Professor of Surgery Director of MIS HPB/LT Rutgers, New Jersey Medical School March 24 th, 2017 Overview
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationAD/HD is a mental disorder, and it often lasts from
short version10 WHAT WE KNOW Managing Medication for Adults with AD/HD AD/HD is a mental disorder, and it often lasts from childhood into adulthood. Medication is the basic part of treatment for adults.
More informationManagement of obesity
From Behavior Modification through Pharmacotherapy to Surgery an Emphasis on the Team Approach Scott D. Isaacs, M.D., F.A.C.P., F.A.C.E. drisaacs@atlantaendocrine.com Understand the physician s role in
More informationCurrent Management of Obesity
Current Management of Obesity Alka M. Kanaya, MD Professor of Medicine, Epidemiology & Biostatistics UCSF, Controversies in Women s Health December 11, 2015 I have nothing to disclose 1 Prevalence of Obesity
More informationNUTRITIONAL SUPPLEMENTS IN OBESITY: WHAT ARE THEY, DO THEY WORK, & ARE THEY SAFE?
NUTRITIONAL SUPPLEMENTS IN OBESITY: WHAT ARE THEY, DO THEY WORK, & ARE THEY SAFE? Stephanie Nichols, Pharm.D., BCPS, BCPP Associate Professor of Psychiatric Pharmacy Husson University, Bangor Maine 1968
More informationSIOFOR mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SIOFOR 850 850mg film-coated tablets METFORMIN HYDROCHLORIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for
More informationPharmacotherapy III: Naltrexone/Bupropion(Contrave ) for Chronic Weight Management. Renuca Modi MD CCFP 2 nd ANNUAL OBESITY UPDATE September 22, 2018
Pharmacotherapy III: Naltrexone/Bupropion(Contrave ) for Chronic Weight Management Renuca Modi MD CCFP 2 nd ANNUAL OBESITY UPDATE September 22, 2018 COI Faculty: Renuca Modi, MD, CCFP Diplomate of the
More informationPharmacists in Medication Adherence in Psychiatric Patients
Pharmacists in Medication Adherence in Psychiatric Patients Mamta Parikh, PharmD, BCPS, BCPP Assistant Professor, Clinical and Administrative Sciences Notre Dame of Maryland University School of Pharmacy
More informationpennsylvania DEPARTMENT OF HUMAN SERVICES
Testimony on Coverage of Anti-Obesity Drugs as a Compensable Service in the Medical Assistance Program Terri Cathers, Pharm. D. Director of Pharmacy Programs Office of Medical Assistance Programs House
More informationOBESITY. Caroline Steinman DO
OBESITY Caroline Steinman DO No financial disclosures DISCLOSURES OUTLINE Statistics Medications Diets Exercise OBESITY STATISTICS IN INDIANA 65.9% overweight(12) 29.6% obese(12) 28.1% of adults report
More informationDisclosures. Objectives. Impact of Obesity in Primary Care Practice and What To Do About It. Intuitive Surgical. Consultant
Disclosures Intuitive Surgical Consultant Stephen Archer, MD, FACS, FASMBS Director, Bariatric Surgery, St. Charles Medical Center Bend, OR Grand Rounds June 15, 2018 2 Objectives Impact of Obesity in
More informationSmoking Cessation Pharmacotherapy Guidelines
Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence
More informationLemilvo Tablets (aripiprazole)
Lemilvo Tablets (aripiprazole) Healthcare Professional Frequently Asked Questions (FAQ) Brochure Bipolar I Disorder in Adolescents Lemilvo (aripiprazole) is indicated for the treatment up to 12 weeks of
More informationObesity D R. A I S H A H A L I E K H Z A I M Y
Obesity D R. A I S H A H A L I E K H Z A I M Y Objectives Definition Pathogenesis of obesity Factors predisposing to obesity Complications of obesity Assessment and screening of obesity Management of obesity
More informationMEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets
MEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets Read this Medication Guide carefully before you start using WELLBUTRIN and each time you get a refill. There may be new information.
More informationMEDICATION GUIDE BuPROPion Hydrochloride Extended-Release Tablets, USP (SR) (byoo-proe-pee-on)
MEDICATION GUIDE BuPROPion Hydrochloride Extended-Release Tablets, USP (SR) (byoo-proe-pee-on) Read this Medication Guide carefully before you start taking Bupropion Hydrochloride Extended-Release Tablets,
More informationElavil (amitriptyline)
Generic name: Amitriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets; 10 mg/ml injection Available in generic: Yes Drug class: Tricyclic antidepressant General Information
More informationNon-surgical Treatment for Adult Obesity
Non-surgical Treatment for Adult Obesity Kathy Foreman, CNP Comprehensive Weight Management and Bariatric Surgery Program The Ohio State University Wexner Medical Center Objectives Definition, prevalence
More informationPre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes
Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including
More informationAPhA March 2016 Annual Meeting Obesity Cases
APhA March 2016 Annual Meeting Obesity Cases Case #1 Pam is a 47 yo obese Caucasian woman; grade school teacher with a history of HTN, HoTR, and depression who presents for her annual physical. CC: I m
More informationHave you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider.
Have you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider. 1 Benefits of Clozapine Clozapine may work when other medications don t. Doctors
More informationCONTRAVE (naltrexone HCl and bupropion HCl) Extended- Release Tablets Initial U.S. Approval: 2014
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CONTRAVE safely and effectively. See full prescribing information for CONTRAVE. CONTRAVE (naltrexone
More information